Ichnos Sciences has a mission to provide breakthrough therapies that will extend and improve lives. A clinical-stage biotech with the spirit of a start-up, Ichnos aims to shift the way the world thinks about innovation through its research and development of transformative bi/multispecific antibody therapies in oncology. Headquartered in New York, N.Y., Ichnos is using its patented BEAT® technology platform to advance a pipeline of drug candidates to treat hematologic cancers and solid tumors.